BioSpace News Archive

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces new interim data from its Phase II TACTI-002 study (also designated KEYNOTE-798) with a data cut-off date of 16 April 2021

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 11 new employees.

PathAI, today announced that new data highlighting the application of its ML-based PathR algorithm to clinical trials as an aid to pathologists will be presented in the American Society of Clinical Oncology (ASCO) Virtual Scientific Program 2021, held from June 4-8, 2021.

Advaccine Biopharmaceuticals (“Advaccine”) announces that the first participants have been successfully dosed in its phase 2 study of ADV110, a respiratory syncytial virus (RSV) prophylactic vaccine candidate, in Australia .

– Data for investigational CD20xCD3 bispecific antibodies and new combination regimens with Polivy showed enhanced clinical benefits for people with non-Hodgkin’s lymphoma in early studies –

Physicians from Dallas-based Texas Oncology and researchers from Seattle-based Navigating Cancer will present two posters highlighting the benefits of electronic patient management at the virtual 2021 ASCO Annual Meeting , which takes place June 4-8, 2021.

Data from oral docetaxel phase I pharmacokinetic study shows oral administration can achieve exposure comparable to IV docetaxel

Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), an oncology company seeking to drive shareholder returns by focusing on the patient, today announced additional details pertaining to Cullinan Pearl’s ongoing Phase 1/2a trial of CLN-081 in Non-Small Cell Lung Cancer (NSCLC) patients whose tumors harbor epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

Survival benefit observed in two treatment settings of previously treated non-small lung cancer patients

Personalized Therapy Biosimulation Predicts with 100% Accuracy ATRA Non-Response in AML Patients with Favorable Genomic Features